Últimas noticias sobre Molecular Templates (NASDAQ:MTEM) Bolsa

Molecular Templates

Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.

Molecular Templates Inc

News

MNTS

Momentus shares are trading higher after the company announced it has signed a contract with SpaceX to join an upcoming Transporter rideshare mission launching as soon as early 2026.

<p>Barclays  analyst Richard Hightower   initiates coverage on Realty Income (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) with a Equal-Weight rating and announces Price Target of $59.</p>


Price Target

Initiation

Analyst Ratings

Barclays Initiates Coverage On Realty Income with Equal-Weight Rating, Announces Price Target of $59

<p><strong>REE Automotive</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REE#NASDAQ">REE</a>) just disclosed its Q3 earnings on Tuesday, December 17, 2024 at 07:15 AM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>REE Automotive missed estimated earnings by -30.0%, reporting an EPS of $-1.12 versus an estimate of $-0.86.</p>
<p>Revenue was down $199 thousand from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat on EPS by $0.54 which was followed by a 18.0% increase in the share price the next day.</p>

<p>To track all earnings releases for REE Automotive <a href="https://www.benzinga.com/quote/REE/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

Insights into REE Automotive Q3 Earnings

Momentus To Deploy DoD And Commercial Payloads On SpaceX Rideshare Mission In 2026 Using Vigoride Orbital Service Vehicle, Offering Cost-Effective LEO Deployment And Hosted Payload Services

<p>Cantor Fitzgerald  analyst Prakhar Agrawal   initiates coverage on TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) with a Overweight rating and announces Price Target of $10.</p>


TLSI

Cantor Fitzgerald Initiates Coverage On TriSalus Life Sciences with Overweight Rating, Announces Price Target of $10

GELS

Gelteq Announces FDA Approval Of Its Suitability Petition For Its Animal Drug Under Development

BYRN

Byrna Technolofiw To Increase Launcher Production By 33%

Guidance

Bank Of America CEO Moynihan Says Real Rate Structures Have To Come Down A Little Bit To Have More Normalcy In The System; We Don't Expect Medium Term Rates Structure To Move Down A Lot

JAGX

Jaguar Health's  Napo Pharmaceuticals Announces FDA Orphan Drug Designation For Crofelemer

<p>Wedbush  analyst Matt Bryson   reiterates Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Outperform and maintains $140 price target.</p>


Reiteration

Wedbush Reiterates Outperform on Micron Technology, Maintains $140 Price Target

WIIM

MRKR

Marker Therapeutics shares are trading higher after the company announced it won a $9.5 million grant to study pancreatic cancer therapy.

<p><i>New decision establishes reimbursement for the clinical use of Tempus ECG-AF, reducing the financial burden of using AI to improve early detection of atrial fibrillation</i></p>


Biotech

General

Tempus AI announced CMS Decision That Will Allow Reimbursement Assessments Of Cardiax Dysfunctions Using Tempus ECG-AF Algorithm.

<p>Barclays  analyst Richard Hightower   initiates coverage on UDR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UDR#NYSE">UDR</a>) with a Overweight rating and announces Price Target of $50.</p>


Barclays Initiates Coverage On UDR with Overweight Rating, Announces Price Target of $50

LPTH

LightPath Technologies Highlights Strategic Shift To Advanced Optics And Imaging Systems, Defense Growth With $500M-$1B U.S. Army Missile Project, Black Diamond Glass Innovation, Commercial Expansion With Mantis Camera, And Leadership Enhancements For Global Expansion

<p>Wedbush  analyst Robert Driscoll   reiterates IDEAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) with a Outperform and maintains $52 price target.</p>


IDYA

Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $52 Price Target

PLCE

The Children's Place Reports Prelim Results, Reports Net Sales For Six-Week Period Ending Dec. 14 Increased 3.4%; Comparable Retail Sales Decreased 8.9%

RMNI

Rimini Street shares are trading higher after Craig-Hallum upgraded the stock from Hold to Buy and raised its price target from $2 to $6.

Ashford Hospitality Trust shares are trading higher after the company announced it launched strategic initiatives and is targeting $50 million of EBITDA improvement.

Macro Economic Events

Econ #s

Economics

Retail Sales Ex Gas/Autos (MoM) (Nov) +0.2% vs +0.4%; +0.2% Prior

<p>U.S. President-elect Donald Trump is set to meet <strong>Netflix&nbsp;Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) co-CEO Ted Sarandos on Tuesday at Trump&#8217;s Mar-a-Lago resort, Reuters cites familiar sources.</p>
<p>Reuters, citing researcher OpenSecrets said Sarandos has traditionally backed Democratic Party candidates by donating to support them.</p>
<p><strong><em>Also Read:</em></strong><em> <a target="_blank" href="https://www.benzinga.com/24/12/42514598/hubspots-ai-powered-tools-set-to-drive-smb-growth-and-crm-innovation-analyst-says" rel="noreferrer noopener">HubSpot To Dominate SMB CRM Space With AI-Driven Platform, Says BofA Analyst</a></em></p>
<p>Let us examine the dynamics between the streaming giant and the U.S. government. Netflix<strong> </strong>co-founder <strong>Reed Hastings</strong> had <a target="_blank" href="https://www.benzinga.com/news/24/07/39932764/kamala-harris-presidential-campaign-secures-7m-from-netflix-co-founder-reed-hastings" rel="noreferrer noopener">committed a record $7 million</a> to a super PAC backing Vice President Kamala Harris&#8217; presidential campaign.</p>
<p>Hastings&#8217; contribution marks his largest single donation to a candidate. Although initially hesitant to endorse Harris following President Joe Biden&#8217;s withdrawal. This pledge followed Harris&#8217; impressive fundraising momentum.</p>
<p>In July, Netflix reportedly experienced a sharp rise in subscription cancellations after Hastings <a target="_blank" href="https://www.benzinga.com/general/entertainment/24/09/41084606/elon-musk-targets-lopsided-anti-trump-donations-by-netflix-employees-as-cancellations-soare" rel="noreferrer noopener">declared his support for Harris</a>.</p>
<p><strong>Tesla Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and <strong>SpaceX</strong> CEO Elon Musk drew attention to the news, pointing to claims of political donation bias among Netflix employees. Bloomberg columnist <strong>Lucas Shaw</strong>, citing research firm Antenna, reported that Netflix&#8217;s U.S. cancellation rate nearly tripled after Hastings publicly endorsed Harris.</p>
<p>In 2022, three Democratic senators urged Netflix to reduce smoking and vaping depictions <a target="_blank" href="https://www.benzinga.com/general/entertainment/22/04/26429457/senators-demand-netflix-reduce-scenes-with-smoking-vaping" rel="noreferrer noopener">in its streaming content</a>.&nbsp;&nbsp;</p>
<p>Sens. Ed Markey (D-MA), Chris Van Hollen (D-MD), and Richard Blumenthal (D-CT) wrote to Netflix co-CEOs Reed Hastings and Ted Sarandos, requesting fewer scenes featuring smoking and vaping in shows and films.</p>
<p>The senators referenced a <strong>Truth Initiative</strong> report, which found that Netflix&#8217;s content—popular among young audiences—has shown more smoking or vaping scenes than any other channel over the past four years.</p>
<p>Shows like The Queen&#8217;s Gambit and The Umbrella Academy were cited for having over 200 instances of smoking or vaping in their respective 2020 seasons.</p>
<p>Last week, Trump shared plans to meet with <strong>Amazon.com Inc&nbsp;</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) founder Jeff Bezos.</p>
<p>Netflix stock surged 96% year-to-date, backed by its diverse content and live events, including the highly expected&nbsp;NFL Christmas Day games. <strong>Oppenheimer&#8217;s</strong> Jason Helfstein hailed Netflix as the sole investable <a target="_blank" href="https://www.benzinga.com/general/sports/24/12/42512587/netflix-analyst-say-its-only-investable-media-stock-projects-150-million-nfl-christmas-day-boost" rel="noreferrer noopener">mainstream media stock</a>. The analyst flagged a $2.2 billion advertising opportunity annually for live events.</p>
<p><strong>Price Action:</strong> NFLX stock traded lower by 0.11% to $920.04 premarket at the last check on Tuesday.</p>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42514450/grindrs-expanding-lgbtq-market-and-20-revenue-growth-impresses-goldman-sachs" target="_blank" rel="noreferrer noopener">Grindr&#8217;s Expanding LGBTQ+ Market and 20% Revenue Growth Impresses Goldman Sachs</a></strong></li>
</ul>
<p><em>Image via Shutterstock</em></p>


Government

Tech

Media

AMZN

NFLX

TSLA

Trump and Netflix Boss Sarandos Set for High-Stakes Mar-a-Lago Meeting

Molecular Templates GAAP EPS of $0.08, revenue of $11.09M beats by $5.19M

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Molecular Templates</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/mtem-stock-quote/"><strong>MTEM</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Molecular Templates reported earnings per share of 8 cents. This was above the analyst estimate for EPS of -78 cents.</li><li>The company reported revenue of $11.09 million.</li><li>This was 87.90% better than the analyst estimate for revenue of $5.90 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/mtem-stock-earnings-molecular-templates-for-q1-of-2024/">MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q1 2024

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>It&rsquo;s time to dive into the biggest pre-market stock movers for Thursday as we check out all of the hottest news this morning!</p>



<p>Moving stocks this morning are earnings reports, new contracts, a CEO change and more.</p>



<p>Let&rsquo;s get into that news below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>Cue Health</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/hlth-stock-quote/"><strong>HLTH</strong></a>) stock is rocketing more than 49% despite <a href="https://investorplace.com/2024/05/why-is-cue-health-hlth-stock-down-40-today/">plans to close its business</a>.</li>



<li><strong>Smart for Life</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/smfl-stock-quote/"><strong>SMFL</strong></a>) shares are soaring over 48% after <a href="https://www.nasdaq.com/press-release/smart-for-life-announces-updates-on-successful-completion-of-restructuring-program">completing a restructuring program</a>.</li>



<li><strong>Molecular Templates</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mtem-stock-quote/"><strong>MTEM</strong></a>) stock is surging more than 30% without any clear news this morning.</li>



<li><strong>OneMedNet </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/onmd-stock-quote/"><strong>ONMD</strong></a>) shares are increasing over 29% after <a href="https://finance.yahoo.com/news/onemednet-inks-agreement-global-top-200500512.html">signing a new contract</a>.</li>



<li><strong>Kintara Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktra-stock-quote/"><strong>KTRA</strong></a>) stock is rising more than 26% alongside heavy pre-market trading.</li>



<li><strong>Cheche </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/ccg-stock-quote/"><strong>CCG</strong></a>) shares are gaining over 21% with its <a href="https://www-thailand--business--news-com.webpkgcache.com/doc/-/s/www.thailand-business-news.com/thailand-prnews/cheche-group-reports-first-quarter-2024-unaudited-financial-results">latest earnings release</a>.</li>



<li><strong>Verb Technology </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/verb-stock-quote/"><strong>VERB</strong></a>) stock is climbing more than 17% with strong early morning trading.</li>



<li><strong>Nexalin Technology</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxl-stock-quote/"><strong>NXL</strong></a>) shares are jumping over 15% despite a lack of news.</li>



<li><strong>Burlington Stores</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/burl-stock-quote/"><strong>BURL</strong></a>) stock is getting a more than 14% boost with its <a href="https://finance.yahoo.com/news/burlington-stores-inc-reports-first-104500806.html">Q1 earnings report</a>.</li>



<li><strong>C3.ai</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/ai-stock-quote/"><strong>AI</strong></a>) shares are up over 14% after <a href="https://www.investors.com/news/technology/c3-ai-stock-ai-stock-c3-ai-earnings-news-q12024/">beating Q1 estimates</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>NovaBay Pharmaceuticals</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/nby-stock-quote/"><strong>NBY</strong></a>) stock is plummeting more than 40% alongside <a href="https://www.nasdaq.com/press-release/novabay-pharmaceuticals-announces-approval-all-proposals-its-2024-annual-meeting">annual shareholder meeting plans</a>.</li>



<li><strong>UiPath </strong>(NYSE:<a href="https://investorplace.com/stock-quotes/path-stock-quote/"><strong>PATH</strong></a>) shares are diving over 30% on <a href="https://www.nasdaq.com/press-release/uipath-re-appoint-daniel-dines-chief-executive-officer-rob-enslin-steps-down-ceo-and">a CEO change</a>.</li>



<li><strong>Innovative Eyewear</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/lucy-stock-quote/"><strong>LUCY</strong></a>) stock is retreating more than 21% on a <a href="https://finance.yahoo.com/news/innovative-eyewear-inc-announces-2-184300125.html">new direct offering</a>.</li>



<li><strong>Sonoma Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/snoa-stock-quote/"><strong>SNOA</strong></a>) shares are tumbling over 18% without any obvious news today.</li>



<li><strong>SCWorx </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/worx-stock-quote/"><strong>WORX</strong></a>) stock is taking a more than 16% beating this morning.</li>



<li><strong>Salesforce </strong>(NYSE:<a href="https://investorplace.com/stock-quotes/crm-stock-quote/"><strong>CRM</strong></a>) shares are dropping over 16% on <a href="https://finance.yahoo.com/video/salesforce-stock-sinking-q2-earnings-202330512.html">poor Q2 guidance</a>.</li>



<li><strong>Onconetix </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/onco-stock-quote/"><strong>ONCO</strong></a>) stock is decreasing close to 16% after an unexpected rally yesterday.</li>



<li><strong>Sharps Technology</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/stss-stock-quote/"><strong>STSS</strong></a>) shares are falling more than 14% <a href="https://investorplace.com/2024/05/why-is-sharps-technology-stss-stock-up-194-today/">following a recent rally</a>.</li>



<li><strong>Fangdd Network</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/duo-stock-quote/"><strong>DUO</strong></a>) stock is slipping over 13% today.</li>



<li><strong>Agilent Technologies</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/a-stock-quote/"><strong>A</strong></a>) shares close out our pre-market stock movers down over 13% on <a href="https://finance.yahoo.com/news/agilent-reports-q2-earnings-key-220003997.html">fiscal Q2 earnings</a>.</li>
</ol><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-may-30th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>There are risks associated with any investment &ndash; there&rsquo;s no such thing as a surefire investment, although tools like the Portfolio Grader can make your life easier when looking for stocks to buy and those to avoid. One of the riskiest investments are in F-rated <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>, and those should be avoided at all costs when you&rsquo;re considering your portfolio.</p>



<p>Penny stocks are low-priced securities, but they really don&rsquo;t cost a penny. Instead, they are shares of stocks that are priced at less than $5 &ndash; still a pittance compared to some of the top names in the market. While some large companies fall into penny stock territory, penny stocks often represent small, less established companies. While the low cost and potential for high returns can make penny stocks appealing to some investors, they come with significant risks, especially when dealing with F-rated penny stocks.</p>



<p>F-rated penny stocks represent companies that have the lowest ratings from the Portfolio Grader based on factors like earnings performance, growth, trading momentum and analyst sentiment. These ratings show poor financial health, unstable management, or dubious business practices.</p>



<p>Another huge issue with F-rated penny stocks is that they are volatile. You have to have a high risk tolerance because these stocks often experience significant price swings within short periods, driven by speculative trading and limited market liquidity. </p>



<p>It is very difficult to predict the day-to-day price movements of penny stocks, which means a bad bet can wipe out your investment pretty quickly.</p>



<p>The names on this list all get &ldquo;F&rdquo; ratings in the Portfolio Grader, and should be avoided this month.</p>



<h2>Tonix Pharmaceuticals (TNXP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/pharmaceuticals_tnxp_1600-300x169.png" alt="medicine research, pharmaceutical background, LJPC stock"><div>Source: Sisacorn / Shutterstock.com</div></div><p><strong>Tonix Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/tnxp-stock-quote/"><strong>TNXP</strong></a>) is a biopharmaceutical company based in New Jersey. The company works on created drugs and therapies to treat disorders of the central nervous system.</p>



<p>It currently has a drug candidate in Phase 3 testing to treat fibromyalgia, and a treatment in Phase 2 trials that would treat long Covid-19 symptoms.</p>



<p>But one of the challenges of investing in pharma companies is the expense. Research and development takes a lot of money, as does the clinical trials. And even after all that, there&rsquo;s never a guarantee that the drug will come to market. That&rsquo;s why investing in a penny pharma stock is particularly dangerous.</p>



<p>Tonix stock fell by 40% in June when it announced a <a href="https://investorplace.com/2024/06/why-is-tonix-pharmaceuticals-tnxp-stock-down-40-today/">proposed public offering</a> to raise money for its continued funding. Investors don&rsquo;t like it when their stock is diluted, andthis is the second time. Tonix also completed a 1-for-32 reverse stock split in June to try oto keep the stock price up.</p>



<p>Even when that reverse split, TNXP stock is barely over $1 per share again. The stock is down 91% this year and gets an &ldquo;F&rdquo; rating in the Portfolio Grader.</p>



<h2>Nauticus Robotics (KITT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/penny-stocks-fingers-300x169.jpg" alt="Image of a penny held between two fingers with a white indoor background. Dividend-Paying Penny Stocks"><div>Source: Shutterstock</div></div><p><strong>Nauticus Robotics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/kitt-stock-quote/"><strong>KITT</strong></a>) is an interesting penny stock. The company makes underwater robots and software that is used by energy, aquaculture and security systems.</p>



<p>Nauticus markets itself as a solution that can help companies manage and maintain offshore wind farms. It says that its robots reduces the need for divers and topside personnel.</p>



<p>But being an interesting company and being a good investment doesn&rsquo;t go hand-in-hand. Nauticus only has a market capitalization of $15 million, and a stock price of roughly 15 cents per share. </p>



<p>That&rsquo;s why the board held a <a href="https://ir.nauticusrobotics.com/sec-filings/all-sec-filings">special meeting on June 17</a> in which it increased the number of unissued common stock shares from 625 million to 5 billion shares. And it also got shareholders to sign off on a reverse stock split that could be as little as 1-to-6 or as much as 1-to-70 shares.</p>



<p>KITT stock popped briefly on the news before returning to its depressed levels. Meanwhile, earnings results for the first quarter showed only $500,000 in revenue compared to $2.8 million a year ago. </p>



<p>The adjusted net loss was $7.4 million for the quarter, which was an improvement from the first quarter a year ago when it lost $10.7 million.</p>



<p>KITT is in rough shape, down 78% this year. It gets an &ldquo;F&rdquo; rating in the Portfolio Grader.</p>



<h2>Mullen Automotive (MULN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/muln_mullen_1600-300x169.png" alt="The Mullen (MULN) Five vehicle is displayed at the 2021 LA Auto Show media day in Los Angeles, November, 18, 2021."><div>Source: Ringo Chiu / Shutterstock.com</div></div><p>I&rsquo;ve been pretty hard on <strong>Mullen Automotive</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/muln-stock-quote/"><strong>MULN</strong></a>), which is an electric vehicle company that&rsquo;s struggling to gain relevance. </p>



<p>I wasn&rsquo;t impressed in 2023 when the company enacted three reverse stock splits, including a 1-for-100 split in December, just so it could remain listed on the Nasdaq.</p>



<p>But Mullen is making a legitimate effort to remake its business by becoming a manufacturer of commercial EVs. It signed a new deal to supply 40 commercial vehicles to a company in&nbsp;<a href="https://finance.yahoo.com/news/mullen-automotive-secures-major-european-183010622.html">Switzerland</a>.&nbsp;It also signed a franchise <a href="https://seekingalpha.com/news/4114510-mullen-enters-new-dealership-and-gets-initial-order?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain">agreement</a> with<strong> </strong><strong>Eco Auto</strong>, a dealership located in Boston, that&rsquo;s focused on EVs.</p>



<p>I appreciate that Mullen is trying to salvage some value. It invoiced $16.3 million in vehicles in the second quarter of fiscal 2024. But losses are still massive, with a net loss of the quarter of $235.3 million and a cash burn of $120 million.</p>



<p>MULN stock is down 82% this year and gets an &ldquo;F&rdquo; rating in the Portfolio Grader.</p>



<h2>Avalon GloboCare (ALBT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/penny-stocks-finding-magnify-300x169.jpg" alt="A hand holding a magnifying glass over pennies. under-$1 stocks to buy. penny stocks to buy"><div>Source: Shutterstock</div></div><p><strong>Avalon GloboCare</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/albt-stock-quote/"><strong>ALBT</strong></a>) is a biotechnology company that develops diagnostic and clinical laboratory products. It&rsquo;s working on a commercial Breathalyzer system that would be a handheld device that can detect acetone levels.</p>



<p>It also has a research project with the Massachusetts Institute of Technology to create a QTY code protein design platform.</p>



<p>The advancements are interesting, but the company has some issues at well. In May it got warning from Nasdaq that as of May 22, the company had not yet filed its first quarter report. <a href="https://www.avalon-globocare.com/investors/sec-filings/quarterly-reports">When the report finally came out</a>, it showed a net loss of $1.36 million, or 12 cents per share, versus a loss of $2.91 million and 29 cents per share in the same quarter a year ago.</p>



<p>Avalon has just over $300,000 in cash on hand, so it will have to be careful with its finances if its going to complete its projects.</p>



<p>ALBT stock is down 14% this year and gets an &ldquo;F&rdquo; rating in the Portfolio Grader.</p>



<h2>ChargePoint Holdings (CHPT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/04/chpt-stock-2-300x169.jpg" alt="EV stocks: A close-up shot of a ChargePoint charging station."><div>Source: YuniqueB / Shutterstock.com</div></div><p><strong>ChargePoint Holdings</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/chpt-stock-quote/"><strong>CHPT</strong></a>) is a good company with a good idea and it simply got outplayed. </p>



<p>The Biden administration is all-in on building out the national infrastructure to power electric vehicles, and it made perfectly good sense for a company like ChargePoint to be in the forefront of making that happen.</p>



<p>But then there&rsquo;s <strong>Tesla</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsla-stock-quote/"><strong>TSLA</strong></a>). Tesla has more than 40,000 charging stations and a powerful automotive company that has a vested interest in getting as many charging stations out there as possible. Tesla&rsquo;s charging stations are all branded with the company&rsquo;s name of course, making them a valuable marketing and advertising tool that just makes Tesla stronger.</p>



<p>Tesla also gets billions of dollars a year by partnering with other automotive companies so they can use the Tesla network.</p>



<p>Where does that leave ChargePoint? Not in a good place. <a href="https://s22.q4cdn.com/779683160/files/doc_financials/2024/2025/q1/CHPT_FY2025-Q1_FINAL.pdf">Earnings</a> for the first quarter of fiscal 2025 showed revenue of $107 million, down 18% from a year ago. The company posted a net loss of $71.8 million, which was a 10% improvement from last year.</p>



<p><em><strong>On Penny Stocks and Low-Volume Stocks:</strong>&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.</em></p>



<p><em><strong>Read More:</strong>&#8239;Penny Stocks &mdash;&nbsp;</em><a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank"><em>How to Profit Without Getting Scammed</em></a></p>



<p><em>On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/market360/2024/06/7-f-rated-penny-stocks-to-avoid-this-june/">7 F-Rated Penny Stocks to Avoid This June</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 F-Rated Penny Stocks to Avoid This June

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Molecular Templates</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/mtem-stock-quote/"><strong>MTEM</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Molecular Templates reported earnings per share of -$1.23. This was above the analyst estimate for EPS of -$1.44.</li><li>The company reported revenue of $572,000.</li><li>This was 33.02% better than the analyst estimate for revenue of $430,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/mtem-stock-earnings-molecular-templates-for-q2-of-2024/">MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q2 2024

Molecular Templates GAAP EPS of -$1.23 misses by $0.12, revenue of $0.6M beats by $0.27M

Bristol, Prime Medicine in deal to develop T-cell therapies

Molecular Templates (MTEM) announced that it has received an expected deficiency notification letter from Nasdaq on November 25. The notice indicat...

Molecular Templates receives noncompliance notice from Nasdaq

Molecular Templates ( ($MTEM) ) has issued an announcement. Jason Kim has resigned as the Company's President, CFO, and Treasurer, effective Decemb...

Molecular Templates Announces Key Leadership Transition

Investing in biotechnology stocks offers a unique opportunity for individuals looking to gain exposure to one of the most dynamic and innovative sectors of the market.

Top Biotech Short Squeeze Stocks

ALBT

BURL

CHPT

CRVO

FCEL

HLTH

KITT

KTRA

LUCY

MTEM

MULN

ONCO

ONMD

PATH

PHAT

PRME

SAVA

SMFL

SNOA

STSS

TNXP

VERB

WORX

Press Releases

Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Molecular Templates, Inc. Provides Interim Update

Financing

Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism

Molecular Templates, Inc. Reports First Quarter  2024 Financial Results and Corporate Update

Health Care

Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update

Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements

Comments

Molecular Templates

Noticias

Últimas noticias sobre Molecular Templates (NASDAQ:MTEM) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL